RxDoctor Payments Data

Maksym Marek, MD

Neurology · Los Angeles, CANPI 1881182079

Payments from drug & device makers

$10,691in general payments, 2019–2025

Across 193 payments — averaging $55.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$7K
  • AbbVie$2K
  • Neurocrine Biosciences, Inc.$394
  • Novartis$214
  • Insightec,inc$110
  • Acorda Therapeutics, Inc$93
  • plus $408 from 12 others

What the payments were for

  • Consulting fees$1,52514%
  • Speaking & faculty fees$5,30050%
  • Food & beverage$3,86636%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,691 in reported general payments places this provider in the 70th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$77,755
Medicare patients
137
Services billed
5,570

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
UbrelvyUbrogepant55$59,288
Nurtec OdtRimegepant Sulfate30$36,310
QuliptaAtogepant27$35,972
Aimovig AutoinjectorErenumab-Aooe14$10,362
Emgality PenGalcanezumab-Gnlm12$8,335
Levetiracetam42$1,350
Baclofen12$933
Gabapentin41$857
Sumatriptan Succinate30$831
Carbamazepine11$828
Carbidopa-LevodopaCarbidopa/Levodopa23$709
Diclofenac Sodium33$546
Propranolol Hcl20$546
Topiramate28$399
Memantine Hcl18$380

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta$2,351$95,26082 claims
PfizerNurtec Odt$7,122$36,31030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,996 neurology providers in California.

Other neurology in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →